UNSPSC 51142517: Amantadine

This classification denotes an antiviral agent and cation channel blocker with the molecular formula C10H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BF4C9Z1J53, chemically known as 1-aminotricyclo(3.3.1.1(sup 3,7))decane but generally known as amantadine, which bears US NIH Compound Identifier 2130. Amantadine most often comes in base and hydrochloride\tforms and is often combined with ribavirin and interferon (alpha).

UNSPSC 51142517 Amantadine is a Commodity code that captures pharmaceutical products purchased by state and local health agencies, though recent solicitation activity under this code's specific designation shows limited direct alignment. State and local governments use codes in this family to procure prescription medications, vaccines, and related pharmaceutical supplies for public health programs, emergency response, and community health initiatives. The issuing bodies include state health and human services departments, county health departments, and cooperative purchasing alliances spanning multiple states. Work solicited ranges from individual drug procurement through competitive bidding to multi-state collaborative purchasing agreements for generic pharmaceuticals and over-the-counter products, with vendors required to meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and standard commercial insurance requirements.

Activity under this code spans multiple states, with recent opportunities concentrated in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries and fixed-fee pricing on a two-year term with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage state interest in direct contracting models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multi-state contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and fee agreement, with products effective July 1, 2026.